COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS IN COLOMBIA

被引：0
|
作者：
Lasalvia, P. [1 ]
Rosselli, D. [2 ]
Castaneda-Cardona, C. [1 ]
Garzon, J. [3 ]
Hernandez, F. [1 ]
Beltran, C. [4 ]
Rojas, M. [4 ]
Lopez, M. C. [5 ]
Sarpong, E. M. [6 ]
机构：
[1] NeuroEconomix, Bogota, Colombia
[2] Pontificia Univ Javeriana, Bogota, Colombia
[3] Hosp San Ignacio, Bogota, Colombia
[4] Merck Sharp & Dohme Ltd, Bogota, Colombia
[5] Merck Sharp & Dhome, Bogota, Colombia
[6] MERCK & CO Inc, Rabway, NJ USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN35
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CEFTOLOZANE/TAZOBACTAM PLUS METRONIDAZOLE AS EMPIRIC THERAPY FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN COLOMBIA
    Lasalvia, P.
    Rosselli, D.
    Castaneda-Cardona, C.
    Garzon, J.
    Hernandez, F.
    Beltran, C.
    Rojas, M.
    Lopez, M. C.
    Sarpong, E. M.
    VALUE IN HEALTH, 2018, 21 : S152 - S153
  • [2] Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
    Teresa L Kauf
    Vimalanand S. Prabhu
    Goran Medic
    Rebekah H. Borse
    Benjamin Miller
    Jennifer Gaultney
    Shuvayu S. Sen
    Anirban Basu
    BMC Infectious Diseases, 17
  • [3] Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
    Kauf, Teresa L.
    Prabhu, Vimalanand S.
    Medic, Goran
    Borse, Rebekah H.
    Miller, Benjamin
    Gaultney, Jennifer
    Sen, Shuvayu S.
    Basu, Anirban
    BMC INFECTIOUS DISEASES, 2017, 17
  • [4] The safety of ceftolozane/tazobactam for the treatment of complicated urinary tract infections
    Bassetti, Matteo
    Vena, Antonio
    Giacobbe, Daniele Roberto
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 533 - 540
  • [5] Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections
    Bassetti, Matteo
    Righi, Elda
    FUTURE MICROBIOLOGY, 2015, 10 (02) : 151 - 160
  • [6] NICE Guidance - Complicated urinary tract infections: ceftolozane/tazobactam
    不详
    BJU INTERNATIONAL, 2018, 121 (06) : 825 - 834
  • [7] Comparing ceftolozane/tazobactam versus piperacillin/tazobactam for the initial empiric therapy of urinary tract infections: A retrospective comparative study
    Nakagawa, Tomomi
    Shigehara, Kazuyoshi
    Shinzawa, Rei
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Izumi, Kouji
    Mizokami, Atsushi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (01) : 12 - 16
  • [8] Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK
    Prabhu, Vimalanand
    Foo, Jason
    Ahir, Harblas
    Sarpong, Eric
    Merchant, Sanjay
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 840 - 849
  • [9] Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy
    Escola-Verge, Laura
    Pigrau, Carlos
    Almirante, Benito
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 1853 - 1867
  • [10] Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane plus tazobactam in the treatment of complicated urinary tract infections
    Wagenlehner, Florian M.
    Alidjanov, Jakhongir F.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) : 959 - 966
12345